Testing a New Drug for Advanced Colon, Rectal, or Pancreatic Cancer
Part of Cancer, Digestive system clinical trials.
This study tests an experimental drug, alone or combined with other treatments, for advanced colon, rectal, or pancreatic cancer that hasn't responded to standard options or cannot be removed by surgery. The goal is to see if it is safe and if it helps shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced colon, rectal, or pancreatic cancer that cannot be surgically removed.
- You are generally able to care for yourself (ECOG performance status 0 or 1).
- Your organs (like liver and kidneys) are functioning well enough.
- You have not had certain prior treatments (like an antibody-drug conjugate with a topoisomerase-1 inhibitor).
- You are willing to use effective birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new experimental drug (PF-08634404) combined with standard chemotherapy for people with stage 4 colorectal cancer who have not yet been treated for their advanced disease. The goal is to see if the combination helps shrink or slow the growth of tumors.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
This trial tests new drugs that target specific RAS mutations in advanced gastrointestinal cancers, like pancreatic or colorectal cancer. It aims to see if these drugs can shrink tumors or slow their growth.
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
This trial tests a new drug combination for people whose pancreatic cancer has grown after their first treatment. The goal is to see if it can help shrink tumors or slow the disease.
Hear when a new Gastrointestinal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.